Key result
Sacubitril/valsartan use was associated with a lower risk of HF-related hospitalization compared with angiotensin receptor antagonists (HR 0.73; 95% CI 0.58-0.91; p=0.006).
Why the study?
The comparative effectiveness of sacubitril/valsartan versus angiotensin receptor antagonist therapy for preventing heart failure-related and all-cause hospitalization in patients with HFrEF needed assessment.
Does sacubitril/valsartan reduce HF-related and all-cause hospitalizations in patients with HFrEF compared to angiotensin receptor antagonists?
Cohort (n=3,927)
Does sacubitril/valsartan reduce HF-related and all-cause hospitalizations in patients with HFrEF compared to angiotensin receptor antagonists?
Hazard Ratio: 0.73 (95% CI 0.58–0.91)
Absolute Event Rate: 13% vs 18%
p-value: p=0.006
In patients with HFrEF, initiation of sacubitril/valsartan after hospital discharge is associated with significantly lower risks of HF-related and all-cause hospitalizations compared to angiotensin receptor antagonists.
May support sacubitril/valsartan post-discharge in HFrEF to lower HF hospitalization risk; hypothesis-generating and needs RCT confirmation.
No takes yet. Share an insight, caveat, or question.
Riaz et al. (2021) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=3,927). Sacubitril/valsartan vs. Angiotensin receptor antagonist was evaluated on HF-related hospitalization (HR 0.73, 95% CI 0.58-0.91, p=0.006). Sacubitril/valsartan use was associated with a lower risk of HF-related hospitalization compared with angiotensin receptor antagonists (HR 0.73; 95% CI 0.58-0.91; p=0.006).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: